Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalMultiple Sclerosis Journal
DOIs
StatePublished - Jan 1 2019

Fingerprint

Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

@article{fd5893219f8146c0837714b3cfef5405,
title = "Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary",
author = "Wingerchuk, {Dean Marko}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1352458519837924",
language = "English (US)",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary

AU - Wingerchuk, Dean Marko

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85063334201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063334201&partnerID=8YFLogxK

U2 - 10.1177/1352458519837924

DO - 10.1177/1352458519837924

M3 - Article

AN - SCOPUS:85063334201

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

ER -